Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study

被引:38
作者
Curro, Daniela [1 ]
Vuolo, Luisa [4 ]
Gualandi, Francesca [5 ]
Bacigalupo, Andrea [5 ]
Roccatagliata, Luca [2 ,3 ]
Capello, Elisabetta [1 ]
Uccelli, Antonio [1 ]
Saccardi, Riccardo [4 ]
Sormani, Maria Pia [2 ]
Mancardi, Gianluigi [1 ,2 ]
机构
[1] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy
[2] Univ Genoa, Dept Hlth Sci, Genoa, Italy
[3] Univ Genoa, MRI Ctr Neurol Dis, Genoa, Italy
[4] Univ Florence, Careggi Univ Hosp, I-50121 Florence, Italy
[5] San Martino Hosp, Bone Marrow Transplantat Unit, Genoa, Italy
关键词
Aggressive multiple sclerosis; autologous hematopoietic stem cell transplantation; conditioning regimen; lympho-ablation; multiple sclerosis; relapsing-remitting multiple sclerosis; transplantation; treatment methods; DOSE IMMUNOSUPPRESSIVE THERAPY; BONE-MARROW-TRANSPLANTATION; EXPERIENCE; ARTHRITIS; SURROGATE; TOXICITY; RELAPSES; LESIONS; MS;
D O I
10.1177/1352458514564484
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Autologous hematopoietic stem cell transplantation (AHSCT) has been successfully used to treat aggressive forms of multiple sclerosis (MS) that are unresponsive to approved therapies. In the last years, in view of the risk of mortality related to the procedure, the utilization of low-intensity conditioning regimens has been considered. Objective: To report magnetic resonance imaging (MRI) and clinical data in a small cohort of patients treated with a low-intensity lympho-ablative regimen, followed by AHSCT. Methods: Seven patients affected by relapsing-remitting MS (RRMS) underwent AHSCT, with cyclophosphamide 120 mg/kg in 2 days as the conditioning regimen; and were then followed with serial MRI evaluations until 36 months, with clinical evaluations until 60 months. Results: The mean number of gadolinium (Gd)-enhancing lesions significantly decreased after treatment, but a complete suppression of inflammatory activity was not obtained. No deaths occurred, but every patient developed adverse events, although not severe. After 5 years of follow-up, two patients remained stable, one patient markedly improved and four patients had a mild progression of the disease. Only one patient experienced a relapse after treatment. Conclusion: A low-intensity conditioning regimen with AHSCT has a profound effect on MRI inflammation and relapses, but is not able to completely abrogate MRI activity and disease progression of aggressive RRMS.
引用
收藏
页码:1423 / 1430
页数:8
相关论文
共 26 条
[1]   Immunoablative therapy as a treatment for aggressive multiple sclerosis [J].
Atkins, H ;
Freedman, M .
NEUROLOGIC CLINICS, 2005, 23 (01) :273-+
[2]   Defining the Intensity of Conditioning Regimens: Working Definitions [J].
Bacigalupo, Andrea ;
Ballen, Karen ;
Rizzo, Doug ;
Giralt, Sergio ;
Lazarus, Hillard ;
Ho, Vincent ;
Apperley, Jane ;
Slavin, Shimon ;
Pasquini, Marcelo ;
Sandmaier, Brenda M. ;
Barrett, John ;
Blaise, Didier ;
Lowski, Robert ;
Horowitz, Mary .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (12) :1628-1633
[3]  
Burt RK, 2009, LANCET NEUROL, V8, P244, DOI 10.1016/S1474-4422(09)70017-1
[4]  
Carreras E, 2003, HAEMATOLOGICA, V88, P306
[5]   Autologous stem cell transplantation in progressive multiple sclerosis - An interim analysis of efficacy [J].
Fassas, A ;
Anagnostopoulos, A ;
Kazis, A ;
Kapinas, K ;
Sakellari, I ;
Kimiskidis, V ;
Smias, C ;
Eleftheriadis, N ;
Tsimourtou, V .
JOURNAL OF CLINICAL IMMUNOLOGY, 2000, 20 (01) :24-30
[6]   Autologous hematopoietic stem cell transplantation for autoimmune diseases [J].
Gratwohl, A ;
Passweg, J ;
Bocelli-Tyndall, C ;
Fassas, A ;
van Laar, JM ;
Farge, D ;
Andolina, M ;
Arnold, R ;
Carreras, E ;
Finke, J ;
Kötter, I ;
Kozak, T ;
Lisukov, I ;
Löwenberg, B ;
Marmont, A ;
Moore, J ;
Saccardi, R ;
Snowden, JA ;
van den Hoogen, F ;
Wulffraat, NM ;
Zhao, XW ;
Tyndall, A .
BONE MARROW TRANSPLANTATION, 2005, 35 (09) :869-879
[7]   High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis [J].
Kozák, T ;
Havrdová, E ;
Pit'ha, J ;
Gregora, E ;
Pytlík, R ;
Maaloufová, J ;
Marecková, H ;
Kobylka, P ;
Vodvárková, S .
BONE MARROW TRANSPLANTATION, 2000, 25 (05) :525-531
[8]   High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience [J].
Krasulova, Eva ;
Trneny, Marek ;
Kozak, Tomas ;
Vackova, Blanka ;
Pohlreich, David ;
Kemlink, David ;
Kobylka, Petr ;
Kovarova, Ivana ;
Lhotakova, Petra ;
Havrdova, Eva .
MULTIPLE SCLEROSIS JOURNAL, 2010, 16 (06) :685-693
[9]   Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience [J].
Mancardi, G. L. ;
Sormani, M. P. ;
Di Gioia, M. ;
Vuolo, L. ;
Gualandi, F. ;
Amato, M. P. ;
Capello, E. ;
Curro, D. ;
Uccelli, A. ;
Bertolotto, A. ;
Gasperini, C. ;
Lugaresi, A. ;
Merelli, E. ;
Meucci, G. ;
Motti, L. ;
Tola, M. R. ;
Scarpini, E. ;
Repice, A. M. ;
Massacesi, L. ;
Saccardi, R. .
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (06) :835-842
[10]   Autologous haematopoietic stem-cell transplantation in multiple sclerosis [J].
Mancardi, Gianluigi ;
Saccardi, Riccardo .
LANCET NEUROLOGY, 2008, 7 (07) :626-636